FDA tracker
Cagrilintide: FDA regulatory status
InvestigationalUpdated Apr 23, 2026
Phase 3 (Novo Nordisk) paired with semaglutide
Editorially reviewedThe Peptide Examiner editorial team, Editorial review · Reviewed Apr 23, 2026
Regulatory notes
No peptide-specific FDA regulatory events tracked yet. See the full FDA enforcement timeline for the broader regulatory context.
What this means for patients
Cagrilintide is investigational. Access is through clinical trial enrollment only. Research-peptide vendors selling it face FDA enforcement risk.